Skip to main content
. Author manuscript; available in PMC: 2014 Jun 2.
Published in final edited form as: Cancer Res. 2013 May 3;73(10):3145–3154. doi: 10.1158/0008-5472.CAN-13-0011

Figure 6.

Figure 6

OS2966 potentiates efficacy of bevacizumab in a glioma model. A, study design of experimental groups with standard bevacizumab therapy at 10 mg/kg biweekly (group I, BEV) versus alternating bevacizumab and OS2966 at 1 mg/kg (group II, low-dose combo). B, inhibition of tumor growth with low-dose combo (group II) was equivalent to high-dose bevacizumab (group I) compared with IgG controls in subcutaneous U87MG xenografts (*, P < 0.05, ANOVA with post hoc Bonferroni test). Shown are mean ± SEM.